Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Stocks Stopping the Presses

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

You saw the headlines. You know your stock price made a big move. But what does that portend for your investment's future?

By pairing the latest news with the collective wisdom of our 170,000-strong Motley Fool CAPS investing community, we might be able to discover whether your stock's latest exploits are a short-term hiccup -- or the start of a much bigger trend.

The following stocks have all made big moves over the past five days:


CAPS Rating (out of 5)

Change Past Week (Nasdaq: DSCM  )



VirnetX Holding (NYSE: VHC  )



Ebix (Nasdaq: EBIX  )



Source:, Motley Fool CAPS.

It looks like CAPS members weren't the only one noticing was selling at a deep discount. Earlier this month, we pointed out it was trading for less than half its 52-week high, and noted its important agreement with MedcoHealth Solutions was expiring at the end of the year (with the possibility for one-year renewals thereafter).

Seems Walgreen (NYSE: WAG  ) took notice too and offered to buy the online pharmacy for $409 million, a 113% premium to its valuation. The Fool's Rick Munarriz thought that was a pricey prescription considering Rite-Aid (NYSE: RAD  ) was unlikely to make a counteroffer, and CVS Caremark (NYSE: CVS  ) was still trying to swallow the prescription benefits management pill it took on when Caremark was acquired.

But by buying, Walgreen was underscoring its commitment to be the preeminent place to have your prescription filled. Last quarter, it achieved a milestone by filling for the first time one in every five prescriptions placed in the retail prescription market, and its growth there exceeded by 3% the overall industry growth rate, according to the industry watchers at IMS Health.

Walgreen's also introduced an iPhone app for prescriptions as well as a mobile communications-friendly website. With 97% of CAPS All-Stars rating to outperform the broad market averages, they saw it had the prescription for growth. Let us know in the comments section below or on the CAPS page whether Walgreen made a mistake in paying the premium it did.

A short course in growth
It would have been easier to figure out why VirnetX Holding has been shooting higher had there actually been some headlines to read about this stock, yet this stock has been gapping higher quickly without any announced news. While a recent Seeking Alpha article was bullish on the communications software specialist, the stock has been moving higher well before then. In fact, the real moves began after AT&T (NYSE: T  ) announced it was buying T-Mobile. The Monday after the deal was announced it jumped 7% higher, and it has been moving up non-stop since then. Short-sellers might be getting squeezed here.

Speaking of squeeze, after VirnetX was able to wring a nine-figure settlement out of Microsoft, it began using the momentum to go after a handful of tech companies as well as wireless carriers rolling out their 4G networks. Since every connected device on the network will be required to have a secure domain name, VirnetX's specialty will be paramount here.

The Fool's Seth Jayson thinks investors might want to look closer at the company's cash flows before diving in here, which is enough for CAPS All-Star kkconway to swear off the stock.

The debate over its patents and how they're applied is bound to be fierce, so let us know on the VirnetX Holding CAPS page whether this stock is ready to rocket higher still.

No assurance on veracity
Aren't accusations of fraud and malfeasance supposed to be reserved for Chinese small cap RTO stocks? Seeking Alpha was again the catalyst for a big price move by a company, but this time insurance software provider Ebix was the target of an anonymous short-seller. As Anders Bylund points out, the Fool's Rule Breakers analyst team has found Ebix CEO Robin Raina a paragon of propriety, but investors apparently were taking no chances and abandoned the company en masse.

Ebix is the leading business exchange operator, particularly in the life insurance and annuities markets, but also has a commanding presence in property and casualty and employee benefits. It's been able to lay low under much of Wall Street's radar, but it is certainly gaining prominence now.

It's said the shortest amount of time ever recorded is the interval between when a light turns green and the car behind you leans on its horn to go, but that's only if you exclude the time it takes a trial lawyer to try and round up a class of investors to file a shareholders lawsuit. Naturally, after Ebix's shares plummeted the lawyers smelled blood and swarmed, figuring it was a good time to find an easy payday. But Ebix has already responded to and dismissed the allegations made by the short-seller, so the parasites looking to feed off of Ebix will likely have to find a new host.

CAPS member ozzfan1317 says a lot of the issues raised in the anonymous report were old news or mistaken:

Basically until 2015 they have a tax holiday on foreign income and then they will pay a more normal rate on it. Also they have Tax loss carry overs which will last another year or so. Furthermore the other statements said blog made were about situations at least 4 to 5 years ago. If you read the blog on seeking Alpha it was nothing more than a short sellers desperation post disguised as research.

Additional rebuttals are now surfacing on Seeking Alpha as well, but you can watch the drama play out by adding Ebix to your watchlist.

Microsoft is a Motley Fool Inside Value selection. Ebix is a Motley Fool Rule Breakers pick. MedcoHealth Solutions is a Motley Fool Stock Advisor recommendation. Motley Fool Options has recommended a diagonal call position on Microsoft. The Fool owns shares of Ebix, and Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. 

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 30, 2011, at 7:15 PM, ctyank99 wrote:

    Rite Aid does have debt. Anyone that follows Rite Aid knows that. That's their biggest challange. The rest of their financial picture is looking brighter, though. They've had three months of increased same store sales. They cloed "loser" stores. They've relocated stores and build some beautiful new stores.

    Rite Aid reported a growth of 1% in same-store sales for the five weeks ended February 26, 2011.

    For the month of February, Rite Aid's front-end same-store sales increased 1.1%. Results moderated from an increase of 2.2% in January 2011.

    Pharmacy same-store sales in February improved 0.9% despite a 243 basis point headwind from new generic introductions. Results improved from a 0.6% increase in January 2011. Prescriptions filled at comparable stores increased 1.3%.

    Total drugstore sales improved 0.1% year over year to $2.438 billion for February 2011. In the five-week period, Prescription revenue contributed 68% of drugstore sales while third party prescription revenue accounted for 96.4% of pharmacy sales.

    Cash flow is not an issue.

    This is all great news as far as I'm concerned. I've been buying RAD and I'm bullish long term.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1467336, ~/Articles/ArticleHandler.aspx, 7/26/2016 10:17:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,505.93 12.87 0.07%
S&P 500 2,172.36 3.88 0.18%
NASD 5,120.35 22.72 0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DSCM.DL $0.00 Down +0.00 +0.00%, inc… CAPS Rating: *****
EBIX $52.78 Up +0.25 +0.48%
Ebix CAPS Rating: ***
CVS $94.21 Up +0.17 +0.18%
CVS Health CAPS Rating: *****
RAD $6.92 Down +0.00 +0.00%
Rite Aid CAPS Rating: ***
T $42.76 Down -0.18 -0.42%
AT and T CAPS Rating: ****
WBA $82.05 Up +0.48 +0.59%
Walgreens Boots Al… CAPS Rating: ****